CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
SOHO 最新进展与后续问题：构建 CAR-T 细胞项目的更新
英文原题：SOHO State of the Art Updates and Next Questions Updates on Building Your CAR-T Cell Program.
查看英文原题
SOHO State of the Art Updates and Next Questions Updates on Building Your CAR-T Cell Program.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
过去十年，CAR-T 细胞疗法显著改变了多种血液系统恶性肿瘤的治疗方案和临床结局。随着 CAR-T 获批用于更早治疗线，符合治疗条件的患者数量迅速增加。为满足需求，需要更多治疗中心。建立细胞治疗项目可能颇具挑战，因此本文分享了作者建立临床细胞治疗项目的经验。
展开英文摘要原文
Chimeric antigen receptor T-cell (CAR-T) therapy has significantly impacted treatment algorithms and clinical outcomes for a variety of patients with hematologic malignancies over the past decade. The field of cellular immunotherapy is currently experiencing a rapid expansion of the number of patients eligible for CAR-T therapies as approvals are being seen in earlier lines of therapy.
With the expanded patients eligible for these therapies, more treatment centers will be necessary to keep up with demand. Building a cellular therapy program can be a daunting task, and therefore, we present our experience with building a clinical cellular therapy program.
论文信息
- 作者
- Voorhees TJ、Bezerra E、Denlinger N、Jaglowski S、de Lima M
- 单位
- The Ohio State University James Comprehensive Cancer Center, Columbus, OH. Electronic address: Timothy.Voorhees@osumc.edu.United States
- 文献类型
- 综述
- 期刊
- Clinical lymphoma, myeloma & leukemia2024 Oct
- 原文标识
- PubMed 38643029 · DOI 10.1016/j.clml.2024.03.007